Krsnaa Diagnost. Q1 FY26 Earnings Analysis

- Growth momentum expected to resume in FY '26 with aspirations to surpass previous levels. - Radiology and pathology volumes are increasing, with a balanced 50:50 revenue mix. - Younger centers, especially in radiology, projected to mature and contribute significantly from FY '26 onwards. - Retail business (B2C) anticipated to contribute 5-8% of revenue in FY '26, growing from ~3.5% in Q4 FY '25. - Retail touch points are expanding rapidly (nearly 4x growth in 1 year), supporting growth. - Overall revenue growth target is around 16%+ for FY '26, with expectations to outperform the industry. - Expansion through PPP tenders and selective asset-light models will sustain growth. - Improvement in infrastructure and operational efficiencies expected to enhance margins alongside growth.

- FY25 revenue grew 16% YoY to INR 7,172 million; EBITDA rose 34% to INR 1,958 million with a 27% margin; net profit up 37% to INR 776 million with 11% margin. - Management expects growth momentum to continue with aspirations to surpass FY25 levels into FY26 and beyond. - Younger centers and new projects, including Maharashtra City MRI centers, are expected to mature and drive growth. - ROCE and ROE have improved quarter-on-quarter, expected to improve further as business matures. - Retail (B2C) segment is gaining traction; expected to contribute 5-8% of revenue in FY26 and improve margins gradually. - FY26 capex planned around INR 100-150 crores, with practical cash outflows significantly lower due to asset-light models. - Margins are expected to stabilize or improve further with operational efficiencies and changing business mix. - Overall, management targets mid-to-high teens growth with improving margins and profitability in coming years.

- For FY '26, planned investments are in the range of INR 100 to 150 crores. - Due to adoption of an asset-light model, actual cash outflow is expected to be significantly less than INR 100 crores. - Investments will focus on implementing sizable tenders won at favorable rates. - Capex mainly targets new radiology centers in Madhya Pradesh, Maharashtra, Delhi, and pathology collection centers in Assam and Orissa. - Collection centers require minimal capex, primarily for basic infrastructure like refrigerators and basic test equipment. - Strategic partnerships involve deferred equipment payments with 7% annual interest to support infrastructure. - Investments align with expanding PPP business and retail network, including a 4x increase in retail touch points across 4 states. - Capex has reduced from INR 193 crores in FY '24 to INR 111 crores in FY '25 due to operational efficiencies and asset-light strategies.

- No explicit mention of any current or planned fundraising through debt or equity in the provided transcript. - The company has a gross debt of INR 1,655 million and cash and cash equivalents of INR 1,760 million as of March 31, 2025, indicating a healthy liquidity position. - Management highlighted disciplined capital expenditure plans (capex of INR 100-150 crores for FY '26) aligned with an asset-light model, suggesting controlled capital requirements. - There is no direct reference to plans for raising fresh capital via debt or equity in the near future. - Focus remains on optimizing operational efficiencies, receivables management, and leveraging existing infrastructure to drive growth. - Any material update on fundraising would likely be communicated separately but is not disclosed in this earnings call.

- The company continues to win tenders and deepen its presence in Tier 2 and Tier 3 cities. - There is a strong forward visibility supported by the order book and upcoming project pipeline. - Specific details of tenders in the pipeline are not disclosed due to competition intensity. - Various sizable tenders already won are expected to require investments of about INR 100-150 crores in FY '26. - The management expresses confidence in surpassing current growth numbers with ongoing implementations. - Overall, the outlook reflects a healthy order book with active pursuit of new government tenders and growing retail business channels.